Literature DB >> 11569779

Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV).

H Wanebo1, P Chougule, N Ready, H Safran, W Ackerley, R J Koness, R McRae, P Nigri, L Leone, K Radie-Keane, P Reiss, T Kennedy.   

Abstract

BACKGROUND: The role of surgery in aggressive chemoradiation protocols for advanced head and neck cancer has been questioned because of the quoted high clinical response rates in many series.
METHODS: The role of surgical resection was examined in an aggressive neoadjuvant protocol of weekly paclitaxel, carboplatin, and radiation for stage III and IV with completion of radiation to 72 Gy if biopsy at the primary site was negative after administration of 45 Gy. Of 43 patients enrolled, 38 completed the protocol. The clinical response was 100% (including 18 complete and 20 partial responses).
RESULTS: The complete pathologic response (negative primary site biopsy at 45 Gy) was 25 of 38 (66%). Of patients who presented with N1 to N3 nodes, neck dissection revealed residual nodal metastases in 22%. Surgical resection of the primary site was required in 13 patients, including 5 with larynx cancer and 2 with base of tongue cancers. Four patients had resection with reconstruction for advanced mandible floor of mouth cancer, and one had resection of nasal-maxillary cancer. Functional resection was performed in 9 of 12 patients. The median progression free and overall survival was 64% and 68%, respectively, at median follow-up of 50 months. Nine patients developed recurrence (three local and six distant). There were no failures in the neck. Salvage surgery was performed in one patient with local and one with distant disease.
CONCLUSIONS: Surgical resection is an essential component of aggressive chemoradiation protocols to ensure tumor control at the primary site and in the neck.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11569779     DOI: 10.1007/s10434-001-0644-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Functional outcome after different oncological interventions in head and neck cancer patients.

Authors:  Thomas Mücke; Janett Koschinski; Stefan Wagenpfeil; Klaus-Dietrich Wolff; Anastasios Kanatas; David A Mitchell; Herbert Deppe; Marco R Kesting
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-06       Impact factor: 4.553

2.  Outcome and histopathologic regression in oral squamous cell carcinoma after preoperative radiochemotherapy.

Authors:  Oliver Driemel; Tobias Ettl; Oliver Kölbl; Torsten E Reichert; Bernd V Dresp; Jürgen Reuther; Hans Pistner
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

3.  Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer.

Authors:  Shang-Wen Chen; Ying-Chun Lin; Rui-Yun Chen; Te-Chun Hsieh; Kuo-Yang Yen; Ji-An Liang; Shih-Neng Yang; Yao-Ching Wang; Ya-Huey Chen; Nan-Haw Chow; Chia-Hung Kao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-16       Impact factor: 9.236

Review 4.  Controversies in management of the neck in head and neck cancer.

Authors:  Madhur Garg; Jonathan J Beitler
Journal:  Curr Treat Options Oncol       Date:  2004-02

Review 5.  Management of the Neck after Treatment with Radiation with or without Chemotherapy.

Authors:  Jesus E Medina; Nilesh Raman Vasan; Greg A Krempl
Journal:  Curr Treat Options Oncol       Date:  2007-06

6.  Neck dissections: radical to conservative.

Authors:  K Harish
Journal:  World J Surg Oncol       Date:  2005-04-18       Impact factor: 2.754

7.  Response-Adapted Treatment Following Radiotherapy in Patients With Resectable Locally Advanced Hypopharyngeal Carcinoma.

Authors:  Xi Luo; Xiaodong Huang; Shaoyan Liu; Xiaolei Wang; Jingwei Luo; Jianping Xiao; Kai Wang; Yuan Qu; Xuesong Chen; Ye Zhang; Jingbo Wang; Jianghu Zhang; Guozhen Xu; Li Gao; Runye Wu; Junlin Yi
Journal:  JAMA Netw Open       Date:  2022-02-01

8.  Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial.

Authors:  Jens von der Grün; Ria Winkelmann; Iris Burck; Daniel Martin; Franz Rödel; Peter Johannes Wild; Katrin Bankov; Andreas Weigert; Ivan-Maximiliano Kur; Christian Brandts; Natalie Filmann; Christian Issing; Philipp Thönissen; Anna Maria Tanneberger; Claus Rödel; Shahram Ghanaati; Panagiotis Balermpas
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

9.  Planned neck dissection following chemo-radiotherapy in advanced HNSCC.

Authors:  Tejpal Gupta; Jai Prakash Agarwal
Journal:  Int Semin Surg Oncol       Date:  2004-09-17

10.  Tongue conservation treatment for oral tongue squamous cell carcinoma with induction chemotherapy, surgery, and risk-adapted adjuvant therapy: A phase II trial.

Authors:  Tsung-Lun Lee; Pei-Yin Wei; Muh-Hwa Yang; Peter Mu-Hsin Chang; Ling-Wei Wang; Shyh-Kuan Tai
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.